[1] |
Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.
Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer
[J]. Journal of International Oncology, 2024, 51(6): 321-325.
|
[2] |
Zhang Baihong, Yue Hongyun.
Advances in anti-tumor drugs with new mechanisms of action
[J]. Journal of International Oncology, 2024, 51(6): 354-358.
|
[3] |
Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.
Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy
[J]. Journal of International Oncology, 2024, 51(5): 257-266.
|
[4] |
Wang Kun, Zhou Zhongxin, Zang Qiwei.
Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection
[J]. Journal of International Oncology, 2024, 51(4): 198-203.
|
[5] |
Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.
Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(3): 137-142.
|
[6] |
Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.
Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes
[J]. Journal of International Oncology, 2024, 51(3): 143-150.
|
[7] |
Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.
Progress of radiotherapy in oligometastatic non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(3): 170-174.
|
[8] |
Li Dan, Li Ruiyao, Li Yinghan, Yu Xiuyan, Wu Xuefeng.
Clinical value of serum miR-19b and miR-744-5p levels in the diagnosis of non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 83-88.
|
[9] |
Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.
Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 89-94.
|
[10] |
Ma Zhenghong, Jiang Chao.
Progress of KRASG12C mutations in non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 95-98.
|
[11] |
Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong.
Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway
[J]. Journal of International Oncology, 2024, 51(1): 21-28.
|
[12] |
He Jiahui, Hu Qinyong.
Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data
[J]. Journal of International Oncology, 2024, 51(1): 29-36.
|
[13] |
Xie Yu, Jiang Cheng, Huang Mingmin, Guo Aibin, Yin Zhenyu, Lin Yongjuan.
Effects of intrathecal infusion chemotherapy on intracranial pressure in non-small cell lung cancer patients with leptomeningeal metastases by ultrasound measurement of optic nerve sheath diameter
[J]. Journal of International Oncology, 2023, 50(9): 532-539.
|
[14] |
Qin Xueqian, Yang Hongyu, Wang Zhen, Wang Mengchao, Zhang Xin.
Progress of bispecific antibody in the treatment of non-small cell lung cancer
[J]. Journal of International Oncology, 2023, 50(9): 558-563.
|
[15] |
Deng Juanjun, Zhao Dayong, Li Miao.
Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer
[J]. Journal of International Oncology, 2023, 50(9): 564-568.
|